Time to Buy Recro Pharma, Inc. (REPH) After Today’s Significant Increase?

February 22, 2018 - By Maria Brooks

Investors sentiment decreased to 1.65 in Q3 2017. Its down 0.56, from 2.21 in 2017Q2. It fall, as 7 investors sold Recro Pharma, Inc. shares while 10 reduced holdings. 5 funds opened positions while 23 raised stakes. 9.63 million shares or 4.72% less from 10.10 million shares in 2017Q2 were reported.
State Of Wisconsin Invest Board invested 0% of its portfolio in Recro Pharma, Inc. (NASDAQ:REPH). California Public Employees Retirement invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). Blackrock reported 998,056 shares or 0% of all its holdings. Strs Ohio reported 0% in Recro Pharma, Inc. (NASDAQ:REPH). Tower Cap Limited Liability (Trc) accumulated 2,895 shares or 0% of the stock. Comml Bank Of Mellon Corporation invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). Bnp Paribas Arbitrage Sa reported 1,329 shares. Geode Cap Mngmt Limited Co owns 115,358 shares for 0% of their portfolio. Legal And General Grp Inc Pcl has invested 0% of its portfolio in Recro Pharma, Inc. (NASDAQ:REPH). Renaissance Techs Limited Liability Corporation reported 98,900 shares stake. The Pennsylvania-based Vanguard Gp has invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). Opus Point Ptnrs Mgmt Limited Liability reported 25,231 shares stake. Northern Trust Corp invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). Alyeska Inv Gp Lp, a Illinois-based fund reported 906,398 shares. Parametric Port Assocs Ltd Company holds 0% or 16,428 shares.

Since December 12, 2017, it had 0 insider buys, and 5 selling transactions for $1.43 million activity. Broadfin Healthcare Master Fund Ltd sold $919,128 worth of Recro Pharma, Inc. (NASDAQ:REPH) on Tuesday, December 12. Another trade for 12,964 shares valued at $115,139 was made by SCP Vitalife Partners (Israel) II – L.P. on Tuesday, January 2.

The stock of Recro Pharma, Inc. (NASDAQ:REPH) is a huge mover today! The stock increased 4.49% or $0.37 during the last trading session, reaching $8.61. About 315,924 shares traded or 153.96% up from the average. Recro Pharma, Inc. (NASDAQ:REPH) has risen 26.61% since February 22, 2017 and is uptrending. It has outperformed by 9.91% the S&P500.
The move comes after 7 months positive chart setup for the $164.69M company. It was reported on Feb, 22 by Barchart.com. We have $8.87 PT which if reached, will make NASDAQ:REPH worth $4.94M more.

Analysts await Recro Pharma, Inc. (NASDAQ:REPH) to report earnings on March, 5. They expect $-0.85 EPS, down 4.94 % or $0.04 from last year’s $-0.81 per share. After $-0.48 actual EPS reported by Recro Pharma, Inc. for the previous quarter, Wall Street now forecasts 77.08 % negative EPS growth.

Recro Pharma, Inc. (NASDAQ:REPH) Ratings Coverage

Among 9 analysts covering Recro Pharma (NASDAQ:REPH), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Recro Pharma had 15 analyst reports since August 25, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, August 29 by Janney Capital. As per Monday, July 31, the company rating was maintained by Roth Capital. The rating was initiated by TH Capital with “Buy” on Friday, September 16. The stock of Recro Pharma, Inc. (NASDAQ:REPH) earned “Buy” rating by Oppenheimer on Tuesday, February 13. The stock of Recro Pharma, Inc. (NASDAQ:REPH) has “Buy” rating given on Friday, September 16 by Roth Capital. H.C. Wainwright initiated it with “Buy” rating and $14 target in Tuesday, November 24 report. The rating was initiated by H.C. Wainwright with “Buy” on Wednesday, September 2. Aegis Capital initiated it with “Buy” rating and $21 target in Monday, November 14 report. The company was maintained on Thursday, November 9 by Roth Capital. The firm has “Hold” rating given on Tuesday, August 25 by Zacks.

More notable recent Recro Pharma, Inc. (NASDAQ:REPH) news were published by: Marketwatch.com which released: “Recro Pharma Inc.” on September 03, 2016, also Globenewswire.com with their article: “Recro Pharma Acquires Novel Neuromuscular Blocking Agents” published on July 05, 2017, Globenewswire.com published: “Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam …” on February 20, 2018. More interesting news about Recro Pharma, Inc. (NASDAQ:REPH) were released by: Seekingalpha.com and their article: “Recro Pharma May Be The Key To The Opioid Epidemic” published on February 07, 2018 as well as Seekingalpha.com‘s news article titled: “Recro Pharma submits US marketing application for lead candidate IV meloxicam” with publication date: July 31, 2017.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company has market cap of $164.69 million. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. It currently has negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: